窪蹋勛圖厙

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 窪蹋勛圖厙 News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

WHAT'S NEW

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jul 28 2025

Full Issue

Viewpoints: It's Now Up To States To Keep Residents Insured; California's Abortion Haven Status Is In Jeopardy

Opinion writers discuss these public health issues.

Over the past decade, the United States has made meaningful progress in expanding health coverage and improving care for millions of Americans. But that progress is now in jeopardy. The newly passed One Big Beautiful Bill Act will have far-reaching consequences for the health insurance of millions of Americans. The Congressional Budget Office estimates that nearly 10 million Americans could lose their health insurance by 2034 as a result of the new legislation. In Massachusetts, officials estimate 300,000 people are at risk of losing their health coverage. (Ashish K. Jha, 7/28)

The sudden closure of five Planned Parenthood clinics in Northern California last week reveals a sad, stark truth: California is not the national haven for abortion rights that it has aspired to be since the Supreme Court overturned Roe v. Wade in 2022. No state could be under Republican rule in Washington, or while federal law trumps state law, the Supreme Court majority opposes abortion rights and clinics are reliant on federal money to survive. (Joe Garofoli, 7/27)

The Food and Drug Administration this month asked Sarepta Therapeutics to suspend shipments of its gene therapy Elevidys. The drug treats Duchenne muscular dystrophy, and few ailments are more wrenching: Young boys lose muscle function as the disease progresses and eventually need wheelchairs, often before theyre teenagers. Some die in their 20s. The stakes here for drug development are enormous if Mr. Trumps regulators crush a drug that has already won FDA approval. Several early gene therapies arent home runs, but drug development is iterative and builds on trial and error. Forget about better drug iterations if the agency kills a company for an emerging safety warning in some patients. (7/27)

As Covid-19 has receded from everyday life, New Yorkers and Americans more generally havent shown much interest in poring over their governments pandemic-era performance. In 2024, congressional Republicans released a deeply partisan Covid-19 report, focused on issues like the lab-leak origin theory. But there has been little neutral analysis of real-time policy decisions aimed at truly learning what worked, what didnt, and what if. The U.K., by contrast, set up a Covid inquiry in June 2022 so that, as a nation, it is better prepared next time. (Nina Schwalbe, 7/28)

Im crying more these days because I recently tapered off antidepressants after nearly 10 years. Escitalopram (the generic version of Lexapro) had long helped improve my mental health with minimal side effects apart from stopping up my tear ducts. Now Im in the process of discovering what my mind is like without the assistance of medication. (Sarah Todd, 7/28)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, June 18
  • Wednesday, June 17
  • Tuesday, June 16
  • Monday, June 15
  • Friday, June 12
  • Thursday, June 11
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 窪蹋勛圖厙
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

穢 2026 KFF